{"filing":{"accession_number":"0001213900-26-068272","cik":"0001448431","ticker":"OPRX","company_name":"OptimizeRx Corp","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294565-8k_optimize.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390026068272/ea0294565-8k_optimize.htm"},"events":[{"id":10814,"run_id":9488,"accession_number":"0001213900-26-068272","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"OptimizeRx held its Annual Meeting on June 9, 2026, with voting results on five proposals including director elections, say-on-pay advisory vote, two Equity Plan amendments, and auditor ratification.","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7223,"accession_number":"0001213900-26-068272","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of Amendment No. 2 to the 2021 Equity Incentive Plan, increasing available shares for awards by 1,000,000 to a total of 5,450,000 shares. This is a compensatory arrangement amendment affecting equity awards available to officers and directors, fitting the exec_compensation category under Item 5.02(e). The increase in equity pool is material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:37.315341+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7224,"accession_number":"0001213900-26-068272","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of OptimizeRx's Annual Meeting held on June 9, 2026, including voting outcomes on five proposals: director elections, say-on-pay advisory vote, two Equity Plan amendments, and auditor ratification. The detailed vote tallies for each proposal are the core content of a shareholder_vote_results event, which is material to investors assessing corporate governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:37.315341+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7223,"accession_number":"0001213900-26-068272","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of Amendment No. 2 to the 2021 Equity Incentive Plan, increasing available shares for awards by 1,000,000 to a total of 5,450,000 shares. This is a compensatory arrangement amendment affecting equity awards available to officers and directors, fitting the exec_compensation category under Item 5.02(e). The increase in equity pool is material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:37.315341+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-06-12"},{"id":7224,"accession_number":"0001213900-26-068272","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the complete results of OptimizeRx's Annual Meeting held on June 9, 2026, including voting outcomes on five proposals: director elections, say-on-pay advisory vote, two Equity Plan amendments, and auditor ratification. The detailed vote tallies for each proposal are the core content of a shareholder_vote_results event, which is material to investors assessing corporate governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:37.315341+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-06-12"}]}